Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21405028 | 0.84 | PPARA (0.38) | AKR1C3AKR1C2SMN1; SMN2EPHX2RAB9A | |
| SCHEMBL26683595 | 0.83 | SMN1; SMN2 (0.36) | NOTUMHSP90AA1HSP90AB1SMN1; SMN2RAB9A | |
| SCHEMBL24102993 | 0.81 | THRB (0.37) | NOTUMHSP90AA1HSP90AB1SMN1; SMN2RAB9A | |
| SCHEMBL18551329 | 0.77 | HCAR2 (0.48) | SMN1; SMN2EPHX2TSHRALDH1A1POLB | |
| SCHEMBL30843547 | 0.77 | AKR1C3 (0.36) | AKR1C3AKR1C2SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL1090646 | 0.76 | NOTUM (0.44) | NOTUMSMN1; SMN2EPHX2RAB9ANPC1 | |
| SCHEMBL30801452 | 0.76 | ADRB2 (0.38) | AKR1C3AKR1C2SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL25308997 | 0.74 | CA1 (0.38) | SMN1; SMN2MEN1POLBKMT2A | |
| SCHEMBL31681540 | 0.74 | SMPD1 (0.36) | AKR1C3AKR1C2SMN1; SMN2KMT2A | |
| SCHEMBL18530364 | 0.73 | AKR1C3 (0.43) | AKR1C3AKR1C2SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092071-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | UNIV MICHIGAN (US) | 2026-04-02 | — | — | US | disclosed |
| WO-2024064316-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 INHIBITORS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024064328-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-03-28 | — | — | WO | disclosed |
| US-20240018158-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED | 2024-01-18 | — | — | US | disclosed |
| US-20240018158-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED | 2024-01-18 | — | — | US | disclosed |
| US-20240018158-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED | 2024-01-18 | — | — | US | disclosed |
| US-11702423-B2 | BRM targeting compounds and associated methods of use | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702423-B2 | BRM targeting compounds and associated methods of use | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-07-18 | — | — | US | disclosed |
| EP-4161935-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics, Incorporated (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-115867554-A | BRM targeting compounds and related methods of use | 普莱鲁德疗法有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20220033409-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS, INCORPORATED | 2022-02-03 | — | — | US | disclosed |
| WO-2021252666-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033409-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRDT, RBX1 | NOTUM 3651/4885AKR1C3 4097/4885AKR1C2 4304/4885 |
| US-11702423-B2 | BRM targeting compounds and associated methods of use | ADRM1, BRDT, RBX1 | NOTUM 3651/4885AKR1C3 4097/4885AKR1C2 4304/4885 |
| US-20240018158-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRDT, RBX1 | NOTUM 3651/4885AKR1C3 4097/4885AKR1C2 4304/4885 |
| US-20260092071-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | SMARCC2, SMARCC1, SMARCA2 | NOTUM 4569/4885AKR1C3 110/4885AKR1C2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.